Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationPaul B. Chapman, Grant A. McArthur, Axel Hauschild et al.|New England Journal of Medicine|2011Cited by 7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> MutationCaroline Robert, Paolo A. Ascierto, Georgina V. Long et al.|New England Journal of Medicine|2014Cited by 5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated MelanomaJames Larkin, Antoni Ribas, Paolo A. Ascierto et al.|New England Journal of Medicine|2014Cited by 2k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A. McArthur, Axel Hauschild, Paul B. Chapman et al.|The Lancet Oncology|2014Cited by 978
Cancer classification using the Immunoscore: a worldwide task forceJérôme Galon, Noriyuki Sato, Franck Pagès et al.|Journal of Translational Medicine|2012Cited by 803